SOURCE: Xechem International Inc.

July 03, 2008 16:35 ET

Xechem International Announces Conference Call to Address Information Update

EDISON, NJ--(Marketwire - July 3, 2008) - Xechem International (PINKSHEETS: XKEM) today announced today that it will be holding a conference call to update shareholders and other interested persons on its business operations and financial status. Details for the call are:

Date: July 10, 2008
To: 9:30 a.m. Central Daylight Time
Dial-In: Domestic: 1-866-548-2692
International: 904-596-2360 - Outside the U.S. & Canada

About Xechem: Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD). Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations and that the Company may be required to seek protection from creditors.

Contact Information

  • Contact:
    Xechem International Inc.
    379 Thornall Street
    Edison, NJ 08837
    (732) 205-0500
    (732) 205-0504 Fax